Patents Issued in September 26, 2019
  • Publication number: 20190290616
    Abstract: Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.
    Type: Application
    Filed: March 22, 2019
    Publication date: September 26, 2019
    Inventors: Uma Sinha, Satish Rao
  • Publication number: 20190290617
    Abstract: The present disclosure relates to a novel use of a sesquiterpene derivative, more particularly to a composition for preventing, improving or treating macular degeneration or macular edema caused by vascular leakage in the eye, the composition containing a sesquiterpene derivative compound represented by Chemical Formula 1 of the present disclosure or a pharmaceutically acceptable salt thereof as an active ingredient. Whereas the intraocular disease-related treating agents available in the market should be injected directly into the vitreous cavity, thus causing pain and side effects, the sesquiterpene derivative compound of the present disclosure is delivered to the target tissue (eye) via different administration routes (oral, intraperitoneal, etc.) other than the intravitreal route. Accordingly, the sesquiterpene derivative compound provides excellent therapeutic effect without being restricted by the administration routes.
    Type: Application
    Filed: October 14, 2016
    Publication date: September 26, 2019
    Applicant: KOOKMIN UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION
    Inventor: Sangtaek OH
  • Publication number: 20190290618
    Abstract: The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
    Type: Application
    Filed: February 25, 2019
    Publication date: September 26, 2019
    Inventors: Kishore M. Gadde, K. Ranga R. Krishnan
  • Publication number: 20190290619
    Abstract: Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceutical compositions including the immunotherapeutic agents and glutamate modulating agents are also disclosed.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 26, 2019
    Inventor: Vladimir CORIC
  • Publication number: 20190290620
    Abstract: The present invention relates to applications of a novel thiazole derivative in treating ulcerative colitis and in the preparation of drugs for treating ulcerative colitis.
    Type: Application
    Filed: May 17, 2017
    Publication date: September 26, 2019
    Inventors: Honglin LI, Zhenjiang ZHAO, Rui WANG, Yufang XU, Wanqi WANG, Yingfang YANG
  • Publication number: 20190290621
    Abstract: Pharmaceutical compositions comprising a combination of a Class I isoform-selective histone deacetylase inhibitor and a protein kinase C modulator are described as well as methods of using these compositions for treating HIV-1 latency.
    Type: Application
    Filed: November 9, 2017
    Publication date: September 26, 2019
    Inventors: Alexander B. Barnes, George Kyei, Brice Albert
  • Publication number: 20190290622
    Abstract: The disclosure relates to compositions and methods of preventing or treating a subject suffering from opioid toxicity or overdose. The method comprises administering to a patient in need of treatment an effective amount of methocinnamox.
    Type: Application
    Filed: March 22, 2019
    Publication date: September 26, 2019
    Inventors: James H. Woods, Charles Patrick France
  • Publication number: 20190290623
    Abstract: A method for the prevention of the onset of pulmonary oxygen toxicity and/or reduction of decrements of pulmonary function due to pulmonary oxygen toxicity comprising administration of a prophylactically effective amount of an anticholinergic, optionally together with a pharmaceutically acceptable excipient.
    Type: Application
    Filed: March 26, 2019
    Publication date: September 26, 2019
    Inventors: Aaron A. Hall, William A. Cronin, Richard T. Mahon, William R. Johnson
  • Publication number: 20190290624
    Abstract: Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
    Type: Application
    Filed: November 1, 2018
    Publication date: September 26, 2019
    Inventors: James Densmore Copp, Ann W. Newman, Anne Luong
  • Publication number: 20190290625
    Abstract: This application relates to a method of treatment with tradipitant, and more particularly, to a method of treatment of pruritus with tradipitant.
    Type: Application
    Filed: June 4, 2019
    Publication date: September 26, 2019
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele
  • Publication number: 20190290626
    Abstract: This application relates to a method of treatment with tradipitant, and more particularly, to a method of treatment of pruritus with tradipitant.
    Type: Application
    Filed: June 4, 2019
    Publication date: September 26, 2019
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele
  • Publication number: 20190290627
    Abstract: The present invention relates to a Pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a JAK inhibitor compound, (b) a Pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.
    Type: Application
    Filed: June 14, 2019
    Publication date: September 26, 2019
    Inventors: Zhu Alexander Cao, Abdel Saci, K. Gary J. Vanasse, Joseph Daniel Growney
  • Publication number: 20190290628
    Abstract: The invention relates to a molecule enabling removal of neurotoxicity observed in neuron cells due to various reasons.
    Type: Application
    Filed: June 10, 2019
    Publication date: September 26, 2019
    Inventors: Ahmet Hacimuftuoglu, Orhan Ates, Nurullah Saracoglu, Ali Taghizadehghalehjoughi, Farrokh Lafzi
  • Publication number: 20190290629
    Abstract: Provided are a niraparib sustained and controlled release pharmaceutical composition and use thereof. The sustained and controlled release pharmaceutical composition contains dissolution-improved niraparib and a matrix polymer used for regulating release rate; the steady-state plasma concentration trough value Cmin,ss of the pharmaceutical composition is 0.5-4 ?M; the steady-state plasma concentration peak value Cmax,ss is 0.8-6 ?M.
    Type: Application
    Filed: June 14, 2019
    Publication date: September 26, 2019
    Applicant: SCIENCE RAINBOW BIOPHARMA CO. LTD
    Inventors: Yong Gan, Bingxue Meng, Yan Liu, Chunliu Zhu, Shiyan Guo
  • Publication number: 20190290630
    Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Application
    Filed: December 21, 2018
    Publication date: September 26, 2019
    Inventors: Sean Caenepeel, Jude Canon, Paul Hughes, Jonathan D. Oliner, Richard J. Rickles, Anne Y. Saiki
  • Publication number: 20190290631
    Abstract: It is an object of the present invention to provide a solid pharmaceutical composition, which can suppress a reduction in the content of an active ingredient caused by decomposition of rapamycin or a derivative thereof due to light irradiation, can ensure long-term stability, and has high storage convenience. In the present invention, the inventors have found that a preparation comprising rapamycin or a derivative thereof wherein a iron oxide is dispersed in the preparation can ensure light stability of the active ingredient, thereby completing the present invention. The present invention relates to a solid pharmaceutical preparation comprising rapamycin or a derivative thereof and iron oxide, wherein the iron oxide is dispersed in the solid pharmaceutical preparation.
    Type: Application
    Filed: May 23, 2017
    Publication date: September 26, 2019
    Applicant: NIPPON KAYAKU KABUSHIKI KAISHA
    Inventor: Dai KAWAMURA
  • Publication number: 20190290632
    Abstract: The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.
    Type: Application
    Filed: February 14, 2019
    Publication date: September 26, 2019
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying Wang, Jason Brewer, Anil Vasudevan, Yanbin Lao, Charles Hutchins, Hongyu Zhao, Huan-Qiu Li
  • Publication number: 20190290633
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Application
    Filed: October 26, 2018
    Publication date: September 26, 2019
    Inventor: Ashley Daugherty
  • Publication number: 20190290634
    Abstract: The invention provides therapeutic compositions that contain an inhibitor of dihydroorotate dehydrogenase (DHODH) and promote sustained elevation of dihydroorotate (DHO) levels in a patient. The compositions are useful for treating disorders associated with unregulated DHODH activity, such as acute myeloid leukemia. The invention also provides methods of determining therapeutically effective doses of compositions that contain a DHODH inhibitor. The invention further provides methods of synthesis of 2-(2?-halo-1-1?-biphenyl-4-yl)-quinoline carboxylic acids, which are useful as DHODH inhibitors.
    Type: Application
    Filed: March 26, 2019
    Publication date: September 26, 2019
    Inventors: Vikram S. Kumar, David P. Hesson
  • Publication number: 20190290635
    Abstract: The invention provides methods of treating brain cancer by providing an agent that inhibits an enzyme in a metabolic pathway in a cancer cell. In some methods of the invention, the agent is an inhibitor of dihydroorotate dehydrogenase. The invention also provides methods of determining a dosage of the therapeutic agent based on measured levels of a metabolite in the pathway.
    Type: Application
    Filed: March 26, 2019
    Publication date: September 26, 2019
    Inventors: Vikram S. Kumar, David P. Hesson
  • Publication number: 20190290636
    Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Application
    Filed: October 26, 2018
    Publication date: September 26, 2019
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
  • Publication number: 20190290637
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R2 to R5, A, X and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 26, 2019
    Inventors: Harald ENGELHARDT, Heribert ARNHOF, Sebastian CAROTTA, Marco Hans HOFMANN, Marc KERENYI, Dirk SCHARN
  • Publication number: 20190290638
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.
    Type: Application
    Filed: June 10, 2019
    Publication date: September 26, 2019
    Inventors: Randall MOREADITH, Michael BENTLEY, Kunsang YOON, Zhihao FANG, Rebecca WEIMER, Bekir DIZMAN, Tacey VIEGAS
  • Publication number: 20190290639
    Abstract: Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described.
    Type: Application
    Filed: June 12, 2019
    Publication date: September 26, 2019
    Inventor: J. Mark JACKSON
  • Publication number: 20190290640
    Abstract: Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.
    Type: Application
    Filed: June 14, 2019
    Publication date: September 26, 2019
    Inventor: Eduardo Dunayevich
  • Publication number: 20190290641
    Abstract: The present invention relates to the field of skin and/or hair repair, for therapeutic and cosmetic purposes. It more specifically relates to an agent stimulating the 5-hydroxytryptamine 1B receptor, for use for boosting skin and/or hair repair.
    Type: Application
    Filed: July 13, 2017
    Publication date: September 26, 2019
    Inventors: Raphael GAILLARD, Fabrice Bruno CHRETIEN, Pierre ROCHETEAU, Nicolas TORNO
  • Publication number: 20190290642
    Abstract: Methods of treating mitochondrial fatty acid b-oxidation and/or transport disorders arising from mutant proteins in the mitochondrial fatty acid ?-oxidation and transport metabolic pathways in patients are provided. The methods modulate the mitochondrial fatty acid ?-oxidation pathway at the last step so that the product of the mutant protein accumulates and stabilizes the mutant protein and/or the substrate(s)/product(s) of the down stream reactions accumulate and possibly bind to allosteric sites on the mutant protein to stabilize it. Trimetazidine pharmacodynamics function as such in the ?-oxidation pathway. Further, a synergistic effect is observed where trimetazidine and PPAR? agonist combination enhanced enzyme activity and presence significantly more than either alone.
    Type: Application
    Filed: November 15, 2017
    Publication date: September 26, 2019
    Inventors: Al-Walid A. Mohsen, Gerard Vockley
  • Publication number: 20190290643
    Abstract: Compositions and methods of using nintedanib for improving the success rate of glaucoma filtration surgery are disclosed herein. Nintedanib can be used alone or in combination with an anti-metabolite drug in a topical or implant eye formulation.
    Type: Application
    Filed: June 12, 2019
    Publication date: September 26, 2019
    Inventors: Jinsong Ni, Rong Yang
  • Publication number: 20190290644
    Abstract: Therapeutic methods of treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) are described. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating subtypes of CLL and SLL using a BTK inhibitor, including subtypes of CLL in patients sensitive to thrombosis and subtypes of CLL that increase monocytes and NK cells in peripheral blood after treatment with a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a combination of a BTK inhibitor and an anti-CD20 antibody.
    Type: Application
    Filed: March 11, 2019
    Publication date: September 26, 2019
    Inventors: Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Brian Lannutti, Todd Covey, Roger Ulrich, Dave Johnson, Tjeerd Barf, Allard Kaptein
  • Publication number: 20190290645
    Abstract: The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.
    Type: Application
    Filed: February 14, 2019
    Publication date: September 26, 2019
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying Wang, Jason Brewer, Anil Vasudevan, Yanbin Lao, Charles Hutchins, Hongyu Zhao, Huan-Qiu Li
  • Publication number: 20190290646
    Abstract: Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.
    Type: Application
    Filed: July 14, 2017
    Publication date: September 26, 2019
    Inventors: James N. WOODY, Patrick SOON-SHIONG
  • Publication number: 20190290647
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 26, 2019
    Applicant: AMGEN INC.
    Inventors: Yinhong CHEN, Mikkel V. DEBENEDETTO, Paul John DRANSFIELD, James S. HARVEY, Jonathan HOUZE, Aarif Yusuf KHAKOO, Su-Jen LAI, Zhihua MA, Nobuko NISHIMURA, Vatee PATTAROPONG, Gayathri SWAMINATH, Wen-Chen YEH, Philip Dean RAMSDEN, Ankit SHARMA
  • Publication number: 20190290648
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 26, 2019
    Applicant: AMGEN INC.
    Inventors: Yinhong CHEN, Paul John DRANSFIELD, James S. HARVEY, Julie Anne HEATH, Jonathan HOUZE, Aarif Yusuf KHAKOO, David J. KOPECKY, Su-Jen LAI, Zhihua MA, Nobuko NISHIMURA, Vatee PATTAROPONG, Gayathri SWAMINATH, Wen-Chen YEH, Philip Dean RAMSDEN
  • Publication number: 20190290649
    Abstract: Compounds of Formula 1 as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed.
    Type: Application
    Filed: March 18, 2019
    Publication date: September 26, 2019
    Inventors: Yinong Xie, Lee E. Babiss
  • Publication number: 20190290650
    Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.
    Type: Application
    Filed: January 18, 2017
    Publication date: September 26, 2019
    Inventors: Manish Kumar Gupta, Parikshit Rameshrao Kulkami, Binuraj Krishnan Nair
  • Publication number: 20190290651
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).
    Type: Application
    Filed: June 10, 2019
    Publication date: September 26, 2019
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • Publication number: 20190290652
    Abstract: The present invention relates to the use of Volasertib or a salt thereof or the hydrate thereof for treating patients suffering from solid malignancies including advanced or metastatic solid malignancies comprising a high frequency administration of Volasertib according to a specific dosage schedule.
    Type: Application
    Filed: June 13, 2019
    Publication date: September 26, 2019
    Inventors: Tillmann TAUBE, Gerd Michael MUNZERT, Dorothea RUDOLPH
  • Publication number: 20190290653
    Abstract: The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrenc
    Type: Application
    Filed: May 17, 2017
    Publication date: September 26, 2019
    Inventors: Doriano FABBRO, Paul HEBEISEN, Petra HILLMANN-WUELLNER, Anton STUETZ, John T. SEYKORA, Florent BEAUFILS
  • Publication number: 20190290654
    Abstract: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: April 1, 2019
    Publication date: September 26, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: John Patrick Maxwell, Paul S. Charifson, Qing Tang, Steven M. Ronkin, Katrina Lee Jackson, Albert Charles Pierce, David J. Lauffer, Pan Li, Simon Giroux, Jinwang Xu, Kevin Michael Cottrell, Mark A. Morris, Nathan D. Waal, John J. Court, Wenxin Gu, Hongbo Deng
  • Publication number: 20190290655
    Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
    Type: Application
    Filed: April 23, 2019
    Publication date: September 26, 2019
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Kimberly VANOVER, Peng LI, Sharon MATES, Robert DAVIS, Lawrence P. WENNOGLE
  • Publication number: 20190290656
    Abstract: The invention provides a novel class of Pt-based anticancer compounds exhibiting multiple anticancer activity.
    Type: Application
    Filed: December 29, 2016
    Publication date: September 26, 2019
    Inventor: Dan Gibson
  • Publication number: 20190290657
    Abstract: Disclosed is a method for treating a condition associated with hyperproliferating cells, the method including the steps of administering to a subject having the condition a composition including at least one cannabinoid receptor agonist, optionally administering to the subject a photodynamic compound, and administering radiation to the subject in whom the at least one cannabinoid receptor agonist is present so as to treat the condition.
    Type: Application
    Filed: March 26, 2019
    Publication date: September 26, 2019
    Inventors: Roger DUMOULIN-WHITE, Arkady MANDEL
  • Publication number: 20190290658
    Abstract: Disclosed herein are compounds, compositions and methods for the treatment of neurological, psychiatric disorders which are characterised by a fundamental disruption of social behaviour, and substance use disorders. In particular, disclosed herein are compounds of Formula (I), or salts or prodrugs thereof. Methods of treating or preventing neurological, psychiatric disorders and substance use disorders, using compounds of Formula (I), or salts and prodrugs are also disclosed.
    Type: Application
    Filed: July 6, 2016
    Publication date: September 26, 2019
    Inventors: Iain Stewart MCGREGOR, Michael KASSIOU, Michael Thomas BOWEN, Callum HICKS, William JORGENSEN
  • Publication number: 20190290659
    Abstract: The present disclosure provides for methods of treating or preventing a cardiovascular disorder and/or a related pulmonary disorder in a subject. In certain embodiments, the method comprises administering a therapeutically effective amount of an inhibitor of Glucose-6-phosphate dehydrogenase (G6PD), or a pharmaceutically acceptable salt, non-salt amorphous form, solvate, poly-morph, tautomer or prodrug thereof.
    Type: Application
    Filed: November 15, 2017
    Publication date: September 26, 2019
    Inventor: Sachin A. GUPTE
  • Publication number: 20190290660
    Abstract: An injectable, flowable composition, kits that include the same, and methods of medical treatment of a mammal (e.g., human) that include the administration of the same are provided.
    Type: Application
    Filed: June 11, 2019
    Publication date: September 26, 2019
    Inventor: Jeffrey Missling
  • Publication number: 20190290661
    Abstract: Disclosed herein are novel methods of treating respiratory diseases, and in particular the treatment of asthmatic children.
    Type: Application
    Filed: June 13, 2019
    Publication date: September 26, 2019
    Inventors: Wilhelm WURST, Thomas BETHKE, Renate ENGELSTAETTER
  • Publication number: 20190290662
    Abstract: Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of acne vulgaris. The compositions include succinic acid and an API selected from the group consisting of salicylic acid, azelaic acid, picolinic acid, benzoyl peroxide, antibiotic, retinoid and combinations thereof in a pharmaceutically acceptable preparation. The compositions that include the combination of succinic acid and another API produce improved efficacy in treating acne vulgaris.
    Type: Application
    Filed: May 18, 2017
    Publication date: September 26, 2019
    Inventors: Lada RASOCHOVA, Michelle KEM
  • Publication number: 20190290663
    Abstract: The present disclosure provides a one-stop surgical method of coronary intervention therapy combined with endovascular aortic repair. The present disclosure specifically provides for the sequential implementation of endovascular aortic repair and coronary intervention therapy in a patient. The present disclosure belongs to the field of medical treatment, and the implementation of the present disclosure has the following advantages: (1) one-stop treatment of two kinds of diseases not only avoids the contradiction in anti-platelet treatment during separate surgeries, but also minimise the potential risk of the separate surgeries; (2) the patient only undergoes one anesthesia and one surgical process for the treatment of two diseases, which is easier to be accepted psychologically; and (3) hospitalization expenses and total hospitalization duration are reduced, and medical resource consumption is reduced.
    Type: Application
    Filed: March 22, 2019
    Publication date: September 26, 2019
    Inventor: YEE TAU TONG
  • Publication number: 20190290664
    Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Application
    Filed: December 3, 2018
    Publication date: September 26, 2019
    Inventor: Herriot Tabuteau
  • Publication number: 20190290665
    Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Application
    Filed: June 12, 2019
    Publication date: September 26, 2019
    Inventor: Herriot Tabuteau